7 Dermatology Headlines You Missed in April 2026

During the month of April 2026, HCPLive highlighted a diverse series of developments across the dermatology landscape, spotlighting recent regulatory momentum, emerging clinical findings, and broader conversations shaping the future of skincare.

Throughout April, coverage from the HCPLive team underscored a steady stream of US Food and Drug Administration (FDA)-related activity, with multiple supplemental New Drug Applications (sNDAs) and expanded indications targeting increasingly specific patient populations, from infants living with atopic dermatitis to adolescents with chronic hand eczema and adults with alopecia areata.

In the following review of April 2026 dermatology news, the updates reflect the continued push toward earlier intervention and age-specific treatment strategies happening in the dermatology space, as well as a growing emphasis on addressing unmet needs in pediatric care:

1. Roflumilast Cream 0.05% sNDA Submitted to FDA for Infants Down to 3 Months with Atopic Dermatitis

The FDA received an sNDA for the broadening of roflumilast cream 0.05% (Zoryve) to treat infants with mild to moderate atopic dermatitis down to the age of 3 months. The sNDA was announced on April 27 by Arcutis Biotherapeutics, with the submission being backed by data drawn from a pair of open-label trials evaluating once-daily treatment with roflumilast cream 0.05% in infants.

2. Upadacitinib sNDA Submitted to FDA for Severe Alopecia Areata

On April 28, AbbVie announced its own sNDA submission for upadacitinib (Rinvoq) as a treatment for severe alopecia areata among adult and adolescent patients with the hair loss condition. The Company’s submission of upadacitinib for alopecia areata in this patient cohort was supported by a set of replicate phase 3 analyses from the UP-AA clinical trial program, with 15 mg and 30 mg once-daily doses having been evaluated by investigators.

3. FDA Expands Dupilumab to Children Aged 2 to 11 Years With Uncontrolled CSU

On April 22, the FDA approved dupilumab (Dupixent) as a therapy for children aged 2 - 11 years with chronic spontaneous urticaria (CSU) who also remain symptomatic despite H1 antihistamine treatment. This joint announcement from Regeneron and Sanofi means the drug’s indication for CSU is extended to adults and adolescents aged 12 years and older. Dupilumab thus became the first biologic medicine in the US for young children suffering from uncontrolled chronic spontaneous urticaria, according to the chief scientific officer at Regeneron.

4. FDA Accepts Delgocitinib sNDA for Chronic Hand Eczema in Adolescents Aged 12–17

In another FDA news release, the agency accepted an sNDA for delgocitinib (Anzupgo) cream as a treatment for patients with moderate-to-severe chronic hand eczema (CHE), specifically adolescents aged 12 - 17 years of age. The decision followed the DELTA TEEN, 16-week, double-blind, vehicle-controlled phase 3 trial’s conclusion, with investigators having assessed 12 - 17-year-olds with TCS-inadequate/inappropriate disease on twice-daily delgocitinib.

5. ABCs in Dermatology: Late Breaking Data Spotlight at AAD 2026

During April’s special edition episode of ABCs in Dermatology, the podcast’s hosts Chris Bunick, MD, PhD, of Yale School of Medicine, and Lindsay Ackerman, MD, of US Dermatology Partners, gave a break down several key late-breaking trials from the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, providing their views on additional data of note across various dermatologic disease states.

6. Skin of Color Savvy: Updates on the AAD Clinical Image Collection, With Vinod Nambudiri, MD, MBA, MPH

In an April Skin of Color Savvy podcast episode, hosted by Skin of Color Society (SOCS) leaders and produced by HCPLive, SOCS leader Vinod Nambudiri, MD, MBA, MPH, a medical dermatologist at Brigham and Women’s Hospital and leader in dermatology education, provided an interview on-site at the AAD meeting regarding his team’s ongoing efforts to improve representation in clinical training resources, as well as several emerging insights on artificial intelligence (AI) and physician well-being.

7. The Medical Sisterhood: Exposure is Power-Women in Medicine Creating Opportunity, With Elizabeth Kiracofe, MD

The most recent episode of The Medical Sisterhood podcast included a conversation between host Mona Shahriari, MD, assistant clinical professor of dermatology at the Yale University School of Medicine, and Elizabeth A. Kiracofe, MD, a board-certified dermatologist and founder of Airia Comprehensive Dermatology. The 2 conducted a candid conversation centered on providing for the community, career evolution, and redefining success as a clinician.